Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis
Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase…